The Pennine Acute Hospitals
NHS Trust Formulary
 
back
6 Endocrine system
06-01-02-03 SGLT-2 inhibitors

In individuals with type 2 diabetes and established cardiovascular disease, SGLT-2 inhibitors with proven cardiovascular benefit (currently empagliflozin and canagliflozin) should be considered


Empagliflozin Jardiance®
Formulary
Tablets
Link  NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
 

View adult BNF  View SPC online  View childrens BNF
Dapagliflozin Forxiga®
Formulary

Tablets

Link  GMMMG NTS: SGLT2 Inhibitors for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
 

View adult BNF  View SPC online  View childrens BNF
Canagliflozin Invokana®
Formulary
Tablets
Link  GMMMG NTS: SGLT2 Inhibitors for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
 

View adult BNF  View SPC online  View childrens BNF